These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7715472)

  • 21. Clinical effects of danazol on endometrial hyperplasia in menopausal and postmenopausal women.
    Soh E; Sato K
    Cancer; 1990 Sep; 66(5):983-8. PubMed ID: 2386926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progesterone administration in patients with absent ovaries.
    Devroey P; Palermo G; Bourgain C; Van Waesberghe L; Smitz J; Van Steirteghem AC
    Int J Fertil; 1989; 34(3):188-93. PubMed ID: 2567713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclic versus continuous medroxyprogesterone acetate for treatment of endometrial hyperplasia without atypia: a 2-year observational study.
    Emarh M
    Arch Gynecol Obstet; 2015 Dec; 292(6):1339-43. PubMed ID: 26015309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endometrial hyperplasia. Risks, recognition and the search for a safe hormone replacement regimen.
    de Lignieres B
    J Reprod Med; 1999 Feb; 44(2 Suppl):191-6. PubMed ID: 11392031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of hyperplasia endometrium with GNRH agonists].
    Radowicki S; Skórzewska K
    Ginekol Pol; 2003 Sep; 74(9):836-9. PubMed ID: 14674133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptorelin: a prospective study.
    Grimbizis G; Tsalikis T; Tzioufa V; Kasapis M; Mantalenakis S
    Hum Reprod; 1999 Feb; 14(2):479-84. PubMed ID: 10099998
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Papillary proliferation of the endometrium: a clinicopathologic study of 59 cases of simple and complex papillae without cytologic atypia.
    Ip PP; Irving JA; McCluggage WG; Clement PB; Young RH
    Am J Surg Pathol; 2013 Feb; 37(2):167-77. PubMed ID: 23211295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study.
    Miles RA; Paulson RJ; Lobo RA; Press MF; Dahmoush L; Sauer MV
    Fertil Steril; 1994 Sep; 62(3):485-90. PubMed ID: 8062942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The endometrium under the effects of hormone replacement therapy in menopause with percutaneous estradiol and low-dose micronized progesterone].
    Philippe E; Faguer B; Engelman A; Charpin C; Loubière R; de Mascarel A; Leduc F; Dupin P; Hemet J; Vauzelle JL
    Pathologica; 1993; 85(1099):475-87. PubMed ID: 8127629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metformin for endometrial hyperplasia.
    Clement NS; Oliver TR; Shiwani H; Sanner JR; Mulvaney CA; Atiomo W
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012214. PubMed ID: 29077194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally.
    Bachmann G; Bouchard C; Hoppe D; Ranganath R; Altomare C; Vieweg A; Graepel J; Helzner E
    Menopause; 2009; 16(4):719-27. PubMed ID: 19436223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
    Katkam RR; Gopalkrishnan K; Chwalisz K; Schillinger E; Puri CP
    Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Diagnosis and therapy of low-risk endometrial hyperplasia. Experience with LH-RH-A].
    Pace S; Stentella P; Frega A; Palazzetti PL; Nobili F; Figliolini M; Grassi A
    Minerva Ginecol; 1992 Dec; 44(12):645-51. PubMed ID: 1491773
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of endometrial hyperplasias with gonadotropin-releasing hormone agonists: pathological, clinical, morphometric, and DNA-cytometric data.
    Agorastos T; Bontis J; Vakiani A; Vavilis D; Constantinidis T
    Gynecol Oncol; 1997 Apr; 65(1):102-14. PubMed ID: 9103399
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of hormone therapy on the endometrium.
    Deligdisch L
    Mod Pathol; 1993 Jan; 6(1):94-106. PubMed ID: 8426860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone.
    Suvanto-Luukkonen E; Malinen H; Sundström H; Penttinen J; Kauppila A
    Acta Obstet Gynecol Scand; 1998 Aug; 77(7):758-63. PubMed ID: 9740525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progesterone pharmacokinetics and pharmacodynamics with 3 dosages and 2 regimens of an effervescent micronized progesterone vaginal insert.
    Paulson RJ; Collins MG; Yankov VI
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4241-9. PubMed ID: 24606090
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bleeding profiles and effects on the endometrium for women using a novel combination of transdermal oestradiol and natural progesterone cream as part of a continuous combined hormone replacement regime.
    Vashisht A; Wadsworth F; Carey A; Carey B; Studd J
    BJOG; 2005 Oct; 112(10):1402-6. PubMed ID: 16167944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaginal micronized progesterone in continuous hormone replacement therapy. A prospective randomized study.
    Ferrero S; Gerbaldo D; Fulcheri E; Cristoforoni P
    Minerva Ginecol; 2002 Dec; 54(6):519-30. PubMed ID: 12432337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasia.
    Haoula ZJ; Walker KF; Powell MC
    Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):176-9. PubMed ID: 21741152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.